The Renaissance and Resilience of CB1 Reverse Agonists: From Central Liabilities to Peripheral Promise

Year : 2026 | Volume : 04 | Issue : 01 | Page : 30 35
    By

    R. Madhumitha Sri,

  • R.M. Aadarshvel,

  • S. Ravichandran*,

  1. Student, Anna University & Validation Analyst (R&D), Zifo Technology, Chennai, Tamil Nadu, India
  2. Student, Lovely Professional University, Jalandhar, Punjab, Chandigarh, India
  3. Professor, St.Peter’s Institute of Higher Education and Research, Chennai, Tamil Nadu, India

Abstract

Building upon these foundational insights, current research has increasingly focused on refining the pharmacological profile of CB1 reverse agonists to maximize therapeutic benefit while minimizing central adverse effects. The adverse neuropsychiatric outcomes associated with first-generation agents such as Rimonabant including anxiety, depression, and suicidal ideation highlighted the critical role of central CB1 receptors in mood regulation. Consequently, drug development strategies have shifted toward peripherally restricted CB1 reverse agonists that exhibit limited blood–brain barrier penetration. These agents selectively target CB1 receptors in metabolic tissues such as the liver, adipose tissue, pancreas, and gastrointestinal tract, thereby preserving central endocannabinoid signaling. Preclinical and early clinical studies of second-generation compounds, such as JD5037 and TM38837, have demonstrated promising results in improving insulin sensitivity, reducing hepatic steatosis, and promoting weight loss without significant central nervous system side effects. Mechanistically, these agents modulate key metabolic pathways, including decreased lipogenesis, enhanced fatty acid oxidation, and improved leptin sensitivity. Additionally, emerging third-generation approaches explore biased signaling and allosteric modulation of CB1 receptors, aiming to fine-tune receptor activity rather than completely suppress it. This nuanced control may further reduce adverse effects while maintaining efficacy. Despite these advances, several challenges remain, including long-term safety validation, variability in patient response, and regulatory hurdles. Moreover, a deeper understanding of the endocannabinoid system’s complex role in human physiology is essential for optimizing therapeutic strategies. As of 2026, CB1-targeted therapies continue to evolve, with peripherally selective and functionally selective agents representing a promising frontier in the treatment of obesity, metabolic syndrome, and related disorders.

Keywords: CB1 receptors, neuropsychiatric, agonists, Rimonabant, CB1 reverse agonists

[This article belongs to International Journal of Cheminformatics ]

How to cite this article:
R. Madhumitha Sri, R.M. Aadarshvel, S. Ravichandran*. The Renaissance and Resilience of CB1 Reverse Agonists: From Central Liabilities to Peripheral Promise. International Journal of Cheminformatics. 2026; 04(01):30-35.
How to cite this URL:
R. Madhumitha Sri, R.M. Aadarshvel, S. Ravichandran*. The Renaissance and Resilience of CB1 Reverse Agonists: From Central Liabilities to Peripheral Promise. International Journal of Cheminformatics. 2026; 04(01):30-35. Available from: https://journals.stmjournals.com/ijci/article=2026/view=242825


References

  1. Gaoni, Y. & Mechoulam, R. (1964). Isolation, structure, and partial synthesis of an active constituent of hashish. Journal of the American Chemical Society.
  2. Rinaldi-Carmona, M., et al. (1994). SR141716A, a potent and selective antagonist of the CB1 receptor. FEBS Letters.
  3. Després, J. P., et al. (2005). Effects of rimonabant on metabolic risk factors in overweight patients. The New England Journal of Medicine.
  4. Christopoulou, A. S., et al. (2024). The evolution of peripherally restricted CB1R antagonists. Nature Reviews Drug Discovery.
  5. Kunos, G., & Tam, J. (2011). The Case for Peripheral CB1 Receptor Blockade in Obesity. Trends in Pharmacological Sciences.
  6. Inversago Pharma. (2025). Clinical trial results for Monlunabant in metabolic disorders. Press Release/Journal of Clinical Endocrinology.
  7. Mallat, A., & Lotersztajn, S. (2011). Cannabinoid receptors as targets for fibrosis. Journal of Hepatology.
  8. Sink, K. S., et al. (2008). The novel cannabinoid CB1 receptor neutral antagonist AM4113. European Journal of Pharmacology.
  9. (2026). Cannabinoid Receptor CB1 Inverse Agonists – Pipeline Insight Report.
  10. Zizzari, P., et al. (2021). Combinatorial therapy with GLP-1 receptor agonists and peripheral CB1 receptor antagonists. Diabetes, Obesity and Metabolism.
Regular Issue Subscription Original Research
Volume 04
Issue 01
Received 22/04/2026
Accepted 22/04/2026
Published 30/04/2026
Publication Time 8 Days
19

Login


My IP

PlumX Metrics